

ForPatients

by Roche

[Renal Cell Cancer \(RCC\)](#) [Pancreatic Cancer](#) [Solid Tumors](#) [Malignant Melanoma](#) [Renal Cell Carcinoma](#) [Cancer Sarcoma](#) [Non Hodgkin Lymphoma \(NHL\)](#) [Lymphoma](#) [Colorectal Cancer \(CRC\)](#) [Non Small Cell Lung Carcinoma](#) [Ovarian Cancer](#) [Breast Cancer](#) [Thyroid Cancer](#) [Melanoma](#) [Head and Neck Neoplasms](#) [Head and Neck Cancer](#)

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Trial Status
Active, not recruiting

Trial Runs In
16 Countries

Trial Identifier
NCT02568267
2015-003385-84,GO40782
RXDX-101-02

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT02568267 2015-003385-84,GO40782 RXDX-101-02
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years

Healthy Volunteers
No
